JPMorgan Chase & Co. Begins Coverage on Upstream Bio (NASDAQ:UPB)

JPMorgan Chase & Co. initiated coverage on shares of Upstream Bio (NASDAQ:UPB) in a research note issued to investors on Tuesday, Marketbeat reports. The brokerage issued an overweight rating and a $38.00 price objective on the stock.

A number of other research firms also recently weighed in on UPB. TD Cowen assumed coverage on shares of Upstream Bio in a research note on Tuesday. They set a “buy” rating on the stock. William Blair started coverage on shares of Upstream Bio in a research note on Tuesday. They set an “outperform” rating on the stock.

Upstream Bio Stock Up 8.9 %

UPB opened at $27.39 on Tuesday. Upstream Bio has a fifty-two week low of $20.74 and a fifty-two week high of $28.98.

Insider Activity

In related news, Director Erez Chimovits purchased 825,000 shares of Upstream Bio stock in a transaction that occurred on Tuesday, October 15th. The shares were acquired at an average price of $17.00 per share, for a total transaction of $14,025,000.00. Following the transaction, the director now directly owns 4,554,873 shares in the company, valued at approximately $77,432,841. This represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. In related news, major shareholder Ai Upstream Llc purchased 1,175,000 shares of Upstream Bio stock in a transaction that occurred on Tuesday, October 15th. The shares were acquired at an average price of $17.00 per share, for a total transaction of $19,975,000.00. Following the transaction, the insider now directly owns 1,175,000 shares in the company, valued at approximately $19,975,000. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Erez Chimovits purchased 825,000 shares of Upstream Bio stock in a transaction that occurred on Tuesday, October 15th. The shares were bought at an average price of $17.00 per share, for a total transaction of $14,025,000.00. Following the transaction, the director now owns 4,554,873 shares in the company, valued at $77,432,841. This represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

Upstream Bio Company Profile

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.